Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma (iNHL)

NCT04038359 is registered in ClinicalTrials.gov with SecuraBio as lead sponsor.

NCT NCT04038359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04038359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma (iNHL)
Lead sponsor
SecuraBio
Phase
Phase 2
Overall status
Completed
Start date
September 24, 2019
Completion date
July 24, 2023
Enrollment
103 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

indolent non-hodgkin lymphoma